Celexion (Key Antibody Assets) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Latest Deal Amount
-
$4M
Celexion (Key Antibody Assets) General Information
Description
Yeast display platform. Platform for generating monoclonal antibodies and other antibody-related assets, which enables highly efficient interrogation of drug targets such as checkpoint proteins.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Buildings and Property
Other Industries
Other Healthcare Technology Systems
Biotechnology
Acquirer
Primary Office
- One Kendall Square
- Suite B6103
- Cambridge, MA 02139
- United States
Celexion (Key Antibody Assets) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Corporate Asset Purchase | 08-Apr-2015 | $4M | 000 | Completed |
Celexion (Key Antibody Assets) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Celexion (Key Antibody Assets) Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Celexion | Corporation | Majority | 000 0000 | 000000 0 |